Conclusions GH001 allows rapid and individualized dosing optimization A single dosing day with GH001 IDR achieved a rapid (within 24 hours) and sustained full remission (7 days) of symptoms of depression in 7/8 patients (87.5%) with TRD GH001 was well tolerated, and no serious adverse events were reported Contacts GH Research: info@ghres.com / clinicaltrials@ghres.com Maastricht University: j.ramaekers@maastrichtuniversity.nl Twitter: @PIMaastricht

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

GH Research plc published this content on 31 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 May 2022 21:21:08 UTC.